Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Acorda Investor Scopia Seeks Big Return From Sale Of The Company

Aug 08 2017

• By Mandy Jackson

Hitting bigger business target

Related Content

Ampyra, Patents, And The Perils Of Letting PTAB Get Your Hopes Up

Apr 04 2017

Will Mitsubishi's High Offer Price For CNS Target NeuroDerm Deter Others?

Jul 24 2017

Acorda's $525m Civitas buy: Sign of Parkinson's deal surge?

Sep 25 2014

Sunovion Adds Parkinson's To CNS Franchise With Cynapsus Buyout

Sep 01 2016

Acorda Picks Up Late-Stage Parkinson's Candidate With $363m Biotie Buy

Jan 19 2016

Deep Breath For Acorda As It Prepares Inhaled Levodopa Filing

Feb 09 2017

Finance Watch: Second Quarter Begins With Solid Base For Biopharma VC, Shaky Ground For Acorda

Apr 10 2017

Related Companies

Acorda Therapeutics, Inc.

Civitas Therapeutics

Biotie Therapies Corp.

Sumitomo Pharma Co., Ltd.

Sumitomo Pharma Co., Ltd.

Mitsubishi Tanabe Pharma Corporation

NeuroDerm, Ltd.

Additional Topics

Business Strategies M & A Deals Companies Commercial Neurology BioPharmaceutical

More from Strategy

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window